Back
Rate this talk
Your peers have not rated this talk yet.
10-minute watch | Talk 1 of 1

ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

Dr Mark Bishton
SYMPOSIUM
ICML

Dr Mark Bishton
University of Nottingham, Nottingham, UK

Dr Mark Bishop, University of Nottingham, Nottingham, UK, highlights the importance of diversity, equity, and inclusion in clinical trial recruitment, and ways to improve equal participation and diversity in clinical trials

Read more

Talks in this series

Dr Mark Bishton presents at ICML (How do we improve outcomes for underserved populations with B-cell malignancies_)
10-minute watch | Talk 1 of 1
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?
Are we ensuring diversity and inclusion in clinical studies?
Dr Mark Bishton presents at ICML (How do we improve outcomes for underserved populations with B-cell malignancies_)
10-minute watch
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

Dr Mark Bishton presents at ICML (How do we improve outcomes for underserved populations with B-cell malignancies_)
10-minute watch | Talk 1 of 1
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?
Are we ensuring diversity and inclusion in clinical studies?
Dr Mark Bishton presents at ICML (How do we improve outcomes for underserved populations with B-cell malignancies_)
10-minute watch
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.